Development of novel N-3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists.

[1]  T. Schirmeister,et al.  Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors , 2016, Journal of enzyme inhibition and medicinal chemistry.

[2]  M. Kurnikova,et al.  Structural Bases of Noncompetitive Inhibition of AMPA-Subtype Ionotropic Glutamate Receptors by Antiepileptic Drugs , 2016, Neuron.

[3]  E. Novellino,et al.  Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation. , 2015, Bioorganic & medicinal chemistry.

[4]  Congzhou Wang,et al.  Mechanism and site of inhibition of AMPA receptors: substitution of one and two methyl groups at the 4-aminophenyl ring of 2,3-benzodiazepine and implications in the "E" site. , 2015, ACS chemical neuroscience.

[5]  T. Schirmeister,et al.  Synthesis and Biological Evaluation of Papain‐Family Cathepsin L‐Like Cysteine Protease Inhibitors Containing a 1,4‐Benzodiazepine Scaffold as Antiprotozoal Agents , 2014, ChemMedChem.

[6]  Congzhou Wang,et al.  Mechanism of Inhibition of the GluA1 AMPA Receptor Channel Opening by the 2,3-Benzodiazepine Compound GYKI 52466 and a N-Methyl-Carbamoyl Derivative , 2014, Biochemistry.

[7]  R. Citraro,et al.  Perspective on the use of perampanel and intravenous carbamazepine for generalized seizures , 2014, Expert opinion on pharmacotherapy.

[8]  Congzhou Wang,et al.  Mechanism and site of inhibition of AMPA receptors: pairing a thiadiazole with a 2,3-benzodiazepine scaffold. , 2014, ACS chemical neuroscience.

[9]  R. Citraro,et al.  Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy , 2014, Expert opinion on therapeutic targets.

[10]  T. Schirmeister,et al.  Development of Rhodesain Inhibitors with a 3‐Bromoisoxazoline Warhead , 2013, ChemMedChem.

[11]  M. Rogawski,et al.  Preclinical pharmacology of perampanel, a selective non‐competitive AMPA receptor antagonist , 2013, Acta neurologica Scandinavica. Supplementum.

[12]  R. Citraro,et al.  New AMPA antagonists in epilepsy , 2012, Expert opinion on investigational drugs.

[13]  S. Grasso,et al.  Mechanism of inhibition of GluA2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives: functional consequences of replacing a 7,8-methylenedioxy with a 7,8-ethylenedioxy moiety. , 2012, Biochemistry.

[14]  J. Weiss.  Ca2+ Permeable AMPA Channels in Diseases of the Nervous System , 2011, Front. Mol. Neurosci..

[15]  Congzhou Wang,et al.  Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: the Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives. , 2011, ACS chemical neuroscience.

[16]  H. Scholz,et al.  Phorbol-Ester Mediated Suppression of hASH1 Synthesis: Multiple Ways to Keep the Level Down , 2011, Front. Mol. Neurosci..

[17]  R. Dingledine,et al.  Glutamate Receptor Ion Channels: Structure, Regulation, and Function , 2010, Pharmacological Reviews.

[18]  S. Ferro,et al.  Combined Strategies for the Discovery of Ionotropic Glutamate Receptor Antagonists , 2009, ChemMedChem.

[19]  R. Citraro,et al.  Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy , 2008, Epilepsy & Behavior.

[20]  A. Cagnotto,et al.  Structure-activity study of 2,3-benzodiazepin-4-ones noncompetitive AMPAR antagonists: identification of the 1-(4-amino-3-methylphenyl)-3,5-dihydro-7,8-ethylenedioxy-4H-2,3-benzodiazepin-4-one as neuroprotective agent. , 2008, Bioorganic & medicinal chemistry.

[21]  S. Grasso,et al.  Mechanism of inhibition of the GluR2 AMPA receptor channel opening by 2,3-benzodiazepine derivatives. , 2008, Biochemistry.

[22]  Hua Shi,et al.  RNA aptamers selected against the GluR2 glutamate receptor channel. , 2007, Biochemistry.

[23]  R. Zukin,et al.  Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death , 2007, Trends in Neurosciences.

[24]  F. Menniti,et al.  Synthesis, chiral resolution, and enantiopharmacology of a potent 2,3-benzodiazepine derivative as noncompetitive AMPA receptor antagonist. , 2006, Journal of medicinal chemistry.

[25]  F. Menniti,et al.  New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[26]  F. Menniti,et al.  Molecular Mechanism of AMPA Receptor Noncompetitive Antagonism , 2005, Neuron.

[27]  J. Henley,et al.  The Molecular Pharmacology and Cell Biology of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors , 2005, Pharmacological Reviews.

[28]  J. Kemp,et al.  Ionotropic and metabotropic glutamate receptor structure and pharmacology , 2005, Psychopharmacology.

[29]  B. Sólyom.  Advanced Pharmacophore Model of Non-Competitive AMPA Antagonist 2,3-benzodiazepines , 2004 .

[30]  Gang Li,et al.  Channel-opening kinetics of GluR2Q(flip) AMPA receptor: a laser-pulse photolysis study. , 2003, Biochemistry.

[31]  F. Menniti,et al.  Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[32]  I. Tarnawa,et al.  Non-competitive AMPA antagonists of 2,3-benzodiazepine type. , 2002, Current pharmaceutical design.

[33]  M. Baraldi,et al.  Synthesis and anticonvulsant activity of novel and potent 2,3-benzodiazepine AMPA/kainate receptor antagonists. , 1999, Journal of medicinal chemistry.

[34]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[35]  C. Parsons,et al.  Glutamate in CNS disorders as a target for drug development: an update. , 1998, Drug news & perspectives.